JP2011516565A5 - - Google Patents

Download PDF

Info

Publication number
JP2011516565A5
JP2011516565A5 JP2011504152A JP2011504152A JP2011516565A5 JP 2011516565 A5 JP2011516565 A5 JP 2011516565A5 JP 2011504152 A JP2011504152 A JP 2011504152A JP 2011504152 A JP2011504152 A JP 2011504152A JP 2011516565 A5 JP2011516565 A5 JP 2011516565A5
Authority
JP
Japan
Prior art keywords
composition
stilbene
agent
trimethoxy
angiogenesis inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011504152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516565A (ja
JP5731372B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/039899 external-priority patent/WO2009126705A2/en
Publication of JP2011516565A publication Critical patent/JP2011516565A/ja
Publication of JP2011516565A5 publication Critical patent/JP2011516565A5/ja
Application granted granted Critical
Publication of JP5731372B2 publication Critical patent/JP5731372B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011504152A 2008-04-10 2009-04-08 癌治療用腫瘍低酸素の誘発 Active JP5731372B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4396408P 2008-04-10 2008-04-10
US61/043,964 2008-04-10
PCT/US2009/039899 WO2009126705A2 (en) 2008-04-10 2009-04-08 Induction of tumor hypoxia for cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015001834A Division JP5944018B2 (ja) 2008-04-10 2015-01-07 癌治療用腫瘍低酸素の誘発

Publications (3)

Publication Number Publication Date
JP2011516565A JP2011516565A (ja) 2011-05-26
JP2011516565A5 true JP2011516565A5 (https=) 2012-04-05
JP5731372B2 JP5731372B2 (ja) 2015-06-10

Family

ID=41162569

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011504152A Active JP5731372B2 (ja) 2008-04-10 2009-04-08 癌治療用腫瘍低酸素の誘発
JP2015001834A Active JP5944018B2 (ja) 2008-04-10 2015-01-07 癌治療用腫瘍低酸素の誘発

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015001834A Active JP5944018B2 (ja) 2008-04-10 2015-01-07 癌治療用腫瘍低酸素の誘発

Country Status (6)

Country Link
US (4) US8591921B2 (https=)
JP (2) JP5731372B2 (https=)
KR (1) KR101925436B1 (https=)
CN (2) CN102026634B (https=)
TW (1) TWI504391B (https=)
WO (1) WO2009126705A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2592103Y2 (ja) 1992-07-23 1999-03-17 東海旅客鉄道株式会社 ケーブルトラフ
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
CN102026634B (zh) 2008-04-10 2014-01-22 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
WO2012009288A2 (en) * 2010-07-12 2012-01-19 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
EP2407161A1 (en) * 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab
US9402820B2 (en) 2011-04-22 2016-08-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors
WO2013096687A1 (en) 2011-12-22 2013-06-27 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
CN102512692B (zh) * 2012-01-16 2014-07-16 北京大学 肿瘤靶向栓塞治疗组合物及其制备方法
AU2013204313C1 (en) * 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
CA2930001A1 (en) * 2013-11-11 2015-05-14 University Hospitals Cleveland Medical Center Targeted treatment of anerobic cancer
US9586056B2 (en) * 2014-07-03 2017-03-07 Haniva Llc Combination therapy for treating cancer and method for treating cancer using a combination therapy
CA2957552C (en) * 2014-08-08 2024-01-16 Vindico Nanobiotechnology, Llc Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
WO2016123313A1 (en) 2015-01-29 2016-08-04 Oxyrase, Inc. Methods for inhibiting tumor growth
EP3294313A4 (en) * 2015-05-15 2019-04-17 The General Hospital Corporation METHODS RELATING TO THE PREVENTION AND TREATMENT OF DRUG RESISTANCE
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
KR20180086195A (ko) * 2015-10-21 2018-07-30 테크리슨 리미티드 면역 매개 암 치료를 위한 조성물 및 방법
ES2865481T3 (es) 2016-04-29 2021-10-15 Poseida Therapeutics Inc Micelas basadas en poli(histidina) para la complejación y el aporte de proteínas y ácidos nucleicos
CN108348463A (zh) * 2016-05-13 2018-07-31 泰克利森有限公司 用于治疗肝脏组织的方法
CN107007571B (zh) * 2017-02-24 2020-08-21 福州市传染病医院 肿瘤微酸性敏感的铜-药物共配位自组装纳米粒及应用
CN110051848A (zh) * 2019-05-06 2019-07-26 中国科学院长春应用化学研究所 药物组合、应用以及抗肿瘤的药物
CN110585214A (zh) * 2019-09-25 2019-12-20 湖北大学 一种促进治疗肿瘤效果的纳米粒子及其合成方法
CN110713596B (zh) * 2019-11-08 2022-04-29 西北师范大学 肿瘤无导管栓塞用pH-还原双响应高分子栓塞剂及其合成
CN112961082B (zh) * 2021-02-22 2022-09-06 沈阳药科大学 一种血管阻断剂与双载药仿生脂质体联用的给药系统
JP7730130B2 (ja) * 2021-03-02 2025-08-27 ドリームメディカルパートナーズ株式会社 塞栓材及びその製造方法
WO2023049207A1 (en) * 2021-09-22 2023-03-30 The University Of Texas System Quantitative magnetic resonance imaging and tumor forecasting
CN114344482B (zh) * 2022-01-14 2023-05-12 重庆医科大学附属第二医院 一种基于金属有机骨架的多功能纳米粒及其制备方法与应用
WO2024006901A1 (en) * 2022-06-29 2024-01-04 Diffusion Pharmaceuticals Llc Uses of bipolar trans carotenoids in the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980779A (en) 1972-02-01 1976-09-14 Bayer Aktiengesellschaft 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxide compositions and method of using same
US5624925A (en) 1986-09-25 1997-04-29 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
US5175287A (en) 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
ATE130517T1 (de) * 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
EP1155689B1 (en) 1993-07-19 2006-09-20 Angiotech Pharmaceuticals, Inc. Anti-angiogenic stents and methods of their preparation
US5484612A (en) 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
GB9404400D0 (en) 1994-03-07 1994-04-20 Wood Pauline J Potentiation of bioreductive agents
CA2281807C (en) 1997-03-07 2007-10-16 Sanofi Pharmaceuticals, Inc. Method of treating a tumor
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
CN1555253A (zh) 2001-09-13 2004-12-15 ������ѧ�����о�Ժ 化疗栓塞用紫杉醇的油性组合物、制剂及它们的制造方法
WO2004064734A2 (en) * 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Combination therapies for the treatment of cancer
US20060264388A1 (en) 2003-02-26 2006-11-23 Olga Valota Method for treating liver cancer by intrahepatic administration of nemorubicin
ITRM20030355A1 (it) 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
CN102026634B (zh) 2008-04-10 2014-01-22 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症

Similar Documents

Publication Publication Date Title
JP2011516565A5 (https=)
CN104043125B (zh) 诱导肿瘤缺氧以治疗癌症
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
CY1119001T1 (el) Ενωσεις 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτων για ανευ νοηματος καταστολη και τη θεραπεια ασθενειας
JP2019507179A5 (https=)
RU2420522C2 (ru) Новый класс ингибиторов гистондеацетилаз
JP5767122B2 (ja) 特定の癌の治療のためのrdea119/bay869766を含む組み合わせ医薬
AU751701B2 (en) Ace inhibitor-MMP inhibitor combinations
JP2013513612A5 (https=)
JP2012519694A5 (https=)
JP2017530983A5 (https=)
JP2010526840A5 (https=)
JP2008531479A5 (https=)
JP2008521827A5 (https=)
JP2006522813A5 (https=)
CN115803328A (zh) 哌嗪-2,3-二酮衍生物及其在医药上的应用
RU2012158142A (ru) Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
JP5788527B2 (ja) キナーゼ阻害剤の副作用低減剤
JP2009538276A5 (https=)
RU2012135396A (ru) Способы лечения рака с применением ингибитора аутофагии на основе тиоксантона
ES2337848T3 (es) Formulaciones de valsartan.
CL2024001520A1 (es) Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales
JP2011524362A5 (https=)
EA201101305A1 (ru) Лечение рака поджелудочной железы
RU2007137115A (ru) Новые офтальмологические композиции и способы их применения